CoChat

The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index; 6 of the 15 sources its claims cite were checked for support.

Tirzepatide leads to weight reduction in people with obesity due to MC4R deficiency

Open access

Abstract

The magnitude of weight reduction in the SURMOUNT-1 trial of the dual GLP-1 and GIP receptor agonist tirzepatide suggests that this treatment may be particularly effective in addressing the treatment needs of people with severe obesity (body mass index >40 kg m−2), some of whom may carry rare penetrant genetic variants. Here we investigated the clinical response of men and women in the SURMOUNT-1 trial who carried pathogenic mutations in the melanocortin 4 receptor (MC4R) gene, the most common genetic cause of obesity. We found that 32 of 2,291 people (1.4%) for whom data were available carried pathogenic MC4R mutations. At baseline, MC4R mutation carriers exhibited a higher body mass index compared with noncarriers (40 kg m−2 versus 38 kg m−2; P = 0.036). In the treatment arm, the weight loss trajectory over 72 weeks was comparable in both groups: 18.3% weight reduction in MC4R mutation carriers versus 19.9% in noncarriers. We conclude that tirzepatide is an effective treatment for the most common genetic subtype of obesity, MC4R deficiency.

Overview

CoChat Summary

TL;DR

In a genetic substudy of SURMOUNT-1, people with obesity carrying pathogenic MC4R mutations lost weight on tirzepatide similarly to noncarriers over 72 weeks. The authors conclude tirzepatide is effective for MC4R deficiency, the most common genetic subtype of obesity.

Key findings

  • Among 2,291 genotyped SURMOUNT-1 participants, 32 (1.4%) carried pathogenic MC4R mutations; carriers had higher baseline BMI than noncarriers (40 kg m−2 versus 38 kg m−2; P = 0.036) and greater waist circumference (120.44 cm versus 114.02 cm; P = 0.012).
  • At 72 weeks, weight reduction was comparable in MC4R mutation carriers versus noncarriers: 18.3% versus 19.9%.
  • The genotype–treatment interaction was not significant (beta coefficient −0.88, SEM 3.2; unadjusted two-sided P = 0.79), and there was no differential impact of treatment versus placebo on metabolic parameters in carriers versus noncarriers.
  • People carrying gain-of-function MC4R variants V103I or I251L (n = 88) were excluded from all analyses.

Methods

  • Post hoc genetic analysis of the randomized controlled SURMOUNT-1 trial of tirzepatide versus placebo in adults with BMI ≥30 kg m−2, or ≥27 kg m−2 with at least one weight-related comorbidity.
  • DNA was available for 2,291 participants (90% of those randomized); samples were genotyped with a customized Affymetrix Axiom Biobank array, yielding 646,504 variants and 2,291 samples after quality control.
  • Weight-loss percentage change at week 72 was analyzed using REGENIE gene-level collapsed burden testing for 14 MC4R loss-of-function mutations with treatment interaction, and mixed-model repeated-measures least-squares means were used to estimate weight trajectories.

Limitations

  • The paper notes that all placebo-treated MC4R mutation carriers were female, which it attributes probably to chance given the rarity of MC4R deficiency and the trial’s female predominance.
  • The paper states that ongoing studies of safety and efficacy of chronic obesity medications are important, and that trials of tirzepatide and other obesity medications in children and adolescents with obesity, including MC4R deficiency, are needed.
  • Evident from the text: the MC4R carrier group was small (n = 32), limiting precision for subgroup comparisons, and the analysis is a genetic substudy of a trial not designed specifically to test tirzepatide efficacy in MC4R deficiency.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1038/s41591-025-03913-2

Cites

25 of 25 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Fig. 1 Baseline BMI distribution and tirzepatide-induced weight loss in MC4R mutation carriers versus noncarriers. a, The distribution of BMI at baseline for MC4R mutation carriers and noncarriers. b, Least-squares mean estimands of the percentage change in body weight from baseline to week 72, with error bars representing 95% confidence intervals (CI). Genetic effects on change in body weight were assessed using aggregated data on carriers of 14 MC4R LoF mutations (beta coefficient −0.88, SEM 3.2); statistical significance was assessed using a REGENIE collapsed burden test incorporating the treatment interaction effect (unadjusted two-sided P value 0.79). c, Time course effect on body weight change. Least-squares mean estimands were generated for each time point based on a three-way interaction among MC4R carrier status, pooled treatment and visit. Blue and gray bars represent tirzepatide treatment and placebo arms, respectively, with error bars representing 95% CI.
Fig. 1 Baseline BMI distribution and tirzepatide-induced weight loss in MC4R mutation carriers versus noncarriers. a, The distribution of BMI at baseline for MC4R mutation carriers and noncarriers. b, Least-squares mean estimands of the percentage change in body weight from baseline to week 72, with error bars representing 95% confidence intervals (CI). Genetic effects on change in body weight were assessed using aggregated data on carriers of 14 MC4R LoF mutations (beta coefficient −0.88, SEM 3.2); statistical significance was assessed using a REGENIE collapsed burden test incorporating the treatment interaction effect (unadjusted two-sided P value 0.79). c, Time course effect on body weight change. Least-squares mean estimands were generated for each time point based on a three-way interaction among MC4R carrier status, pooled treatment and visit. Blue and gray bars represent tirzepatide treatment and placebo arms, respectively, with error bars representing 95% CI.CC BY · PubMed Central

Verification

Claims the paper makes

4 Valid · 2 Not valid · 4 Not checked · 18 Own results and interpretations

15 more claims

Create a free account to see all 28 claims and to verify the 9 references still open.

See all claims — free account
  • Probably not a substantial claim. 8
  • It may state two separate claims as one. 1

Create a free account to see these claims.

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

2 of 2

Citations

Cites

Show all 24 references

Cited by

See all 24

Metadata

Authors
Bhatnagar, P., Ahmad, N. N., Li, X., Coghlan, M., Kaplan, L. M., & Farooqi, I. S.
Affiliations
  • Eli Lilly (United States) (US)
  • Dartmouth College (US)
  • Wellcome/MRC Institute of Metabolic Science (GB)
Corresponding author
Farooqi, I. Sadaf
Venue
Nature Medicine
Published
2025-08-26
Volume
31
Issue
10
Pages
3294-3296
ISSN
  • 1078-8956 (ISSN-L)
  • 1546-170X
OpenAlex
W4413706535
Cited by
20
References
24
Citations by year
2026: 18 · 2025: 2
FWCI
11.23
Type
journal article
Language
en
Open access
Licence
Locations
  • Nature Medicine (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Apollo (University of Cambridge) (submittedVersion, cc-by)
  • Apollo (cc-by)
Funders
  • Eli Lilly and Company
  • Wellcome Trust (207462/Z/17/Z)
  • Government of the United Kingdom
  • National Institute for Health and Care Research
  • Department of Health and Social Care
  • Fondation Botnar
Topics
  • Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
  • Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
  • Health Sciences › Medicine › Surgery › Bariatric Surgery and Outcomes
Keywords
tirzepatide, melanocortin-4 receptor, genetic obesity, morbid obesity, weight loss, GLP-1 receptor agonists, GIP receptor agonist, pathogenic variants, body mass index
MeSH terms
Tirzepatide, Adult, Female, Humans, Male, Middle Aged, Mutation, Obesity, Receptors, Gastrointestinal Hormone, Weight Loss, Body Mass Index, Receptor, Melanocortin, Type 4

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-05, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-05 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Tirzepatide leads to weight reduction in people with obesity due to MC4R deficiency. https://app.cochat.ai/papers/10.1038/s41591-025-03913-2
The paper
Bhatnagar, P., Ahmad, N. N., Li, X., Coghlan, M., Kaplan, L. M., & Farooqi, I. S. (2025). Tirzepatide leads to weight reduction in people with obesity due to MC4R deficiency. Nature Medicine. https://doi.org/10.1038/s41591-025-03913-2

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.